Log in

Relevant bibliographies by topics / Nanoparticles, Breast Cancer, BOS / Journal articles

To see the other types of publications on this topic, follow the link: Nanoparticles, Breast Cancer, BOS.

Journal articles on the topic 'Nanoparticles, Breast Cancer, BOS'

Author: Grafiati

Published: 9 March 2023

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Nanoparticles, Breast Cancer, BOS.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Carney, Christine P., Nikhil Pandey, Anshika Kapur, Graeme F. Woodworth, Jeffrey A. Winkles, and Anthony J. Kim. "Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases." Drug Delivery and Translational Research 11, no. 6 (October 30, 2021): 2344–70. http://dx.doi.org/10.1007/s13346-021-01039-9.

Full text

Abstract:

AbstractBrain metastases (BMs) are the most common type of brain tumor, and the incidence among breast cancer (BC) patients has been steadily increasing over the past two decades. Indeed, ~ 30% of all patients with metastatic BC will develop BMs, and due to few effective treatments, many will succumb to the disease within a year. Historically, patients with BMs have been largely excluded from clinical trials investigating systemic therapies including immunotherapies (ITs) due to limited brain penetration of systemically administered drugs combined with previous assumptions that BMs are poorly immunogenic. It is now understood that the central nervous system (CNS) is an immunologically distinct site and there is increasing evidence that enhancing immune responses to BCBMs will improve patient outcomes and the efficacy of current treatment regimens. Progress in IT for BCBMs, however, has been slow due to several intrinsic limitations to drug delivery within the brain, substantial safety concerns, and few known targets for BCBM IT. Emerging studies demonstrate that nanomedicine may be a powerful approach to overcome such limitations, and has the potential to greatly improve IT strategies for BMs specifically. This review summarizes the evidence for IT as an effective strategy for BCBM treatment and focuses on the nanotherapeutic strategies currently being explored for BCBMs including targeting the blood–brain/tumor barrier (BBB/BTB), tumor cells, and tumor-supporting immune cells for concentrated drug release within BCBMs, as well as use of nanoparticles (NPs) for delivering immunomodulatory agents, for inducing immunogenic cell death, or for potentiating anti-tumor T cell responses. Graphical abstract

APA, Harvard, Vancouver, ISO, and other styles

2

Idhayadhulla, Akbar, Aseer Manilal, Anis Ahamed, Saud Alarifi, and Gurusamy Raman. "Potato Peels Mediated Synthesis of Cu(II)-nanoparticles from Tyrosinase Reacted with bis-(N-aminoethylethanolamine) (Tyr-Cu(II)-AEEA NPs) and Their Cytotoxicity against Michigan Cancer Foundation-7 Breast Cancer Cell Line." Molecules 26, no. 21 (November 3, 2021): 6665. http://dx.doi.org/10.3390/molecules26216665.

Full text

Abstract:

The synthesis of nanoparticles is most important in the context of cancer therapy, particularly copper nanoparticles, which are widely used. In this work, copper(II)-tyrosinase was isolated from potato peel powder. Copper nanoparticles (Tyr-Cu(II)-AEEA NPs) were synthesized via the reaction of tyrosinase with N-aminoethylethanolamine to produce Cu(II)-NPs and these were characterized by means of FT-IR, UV-Spectroscopy, XRD, SEM, TEM and a particle size analyzer. These Tyr-Cu(II)-AEEA NPs were tested as anticancer agents against MCF-7 breast cancer cells. Fluorescence microscopy and DNA fragmentation were also performed, which revealed the inhibiting potentials of Cu(II)-AEEA NPs and consequent cell death; Tyr-Cu(II)-AEEA NPs show potential cytotoxicity activity and this nano material could be contemplated as an anticancer medicament in future investigations.

APA, Harvard, Vancouver, ISO, and other styles

3

Padayachee, Jananee, and Moganavelli Singh. "Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials." Nanobiomedicine 7 (January 1, 2020): 184954352098319. http://dx.doi.org/10.1177/1849543520983196.

Full text

Abstract:

Globally, approximately 1 in 4 cancers in women are diagnosed as breast cancer (BC). Despite significant advances in the diagnosis and therapy BCs, many patients develop metastases or relapses. Hence, novel therapeutic strategies are required, that can selectively and efficiently kill malignant cells. Direct targeting of the genetic and epigenetic aberrations that occur in BC development is a promising strategy to overcome the limitations of current therapies, which target the tumour phenotype. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system, composed of only an easily modifiable single guide RNA (sgRNA) sequence bound to a Cas9 nuclease, has revolutionised genome editing due to its simplicity and efficiency compared to earlier systems. CRISPR/Cas9 and its associated catalytically inactivated dCas9 variants facilitate the knockout of overexpressed genes, correction of mutations in inactivated genes, and reprogramming of the epigenetic landscape to impair BC growth. To achieve efficient genome editing in vivo, a vector is required to deliver the components to target cells. Gold nanomaterials, including gold nanoparticles and nanoclusters, display many advantageous characteristics that have facilitated their widespread use in theranostics, as delivery vehicles, and imaging and photothermal agents. This review highlights the therapeutic applications of CRISPR/Cas9 in treating BCs, and briefly describes gold nanomaterials and their potential in CRISPR/Cas9 delivery.

APA, Harvard, Vancouver, ISO, and other styles

4

Odeyemi, Samuel Wale, and Anthony Jide Afolayan. "Characterization and Cytotoxicity Evaluation of Biologically Synthesized Silver Nanoparticles from Albuca setosa Aqueous Bulb Extract." International Journal of Nanoscience 18, no. 02 (January 30, 2019): 1850023. http://dx.doi.org/10.1142/s0219581x18500230.

Full text

Abstract:

Biologically synthesized nanoparticles are rapidly evolving because it is cost effective and eco-friendly, this also contributes to its preference over nanoparticles from other sources. In this study, silver nanoparticles were synthesized from Albuca setosa aqueous bulb (ASB) extracts and the biological activities evaluated. The silver nanoparticles were synthesized from ASB extracts using silver nitrate and characterized using UV–visible spectroscopy (UV–Vis), Fourier transform infrared spectroscopy (FTIR), scanning electron microscope (SEM), energy dispersive X-ray spectroscopy (EDX), X-ray diffraction (XRD) and transmission electron microscopy (TEM). The antioxidant activity was determined by evaluating the effect on 2,2-diphenyl-2-picrylhydrazyl (DPPH) scavenging activity, 2,2[Formula: see text]-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid diammonium salt (ABTS). The antibacterial potential was investigated on selected Gram positive and Gram negative bacteria while the cytotoxicity was evaluated on MDA-MB-231 breast cancer cells (ATCC HTB-26). Albuca setosa silver nanoparticles (AS-AgNPs) was formed within 60 min reaction time of UV–Vis absorption. The FTIR showed that acid anhydride, alkene, amine, aldehyde, ester, ketone and carbonyl groups contributed to the synthesis of the AS-AgNPs, while SEM and TEM showed stable irregular shaped monodispersed silver nanoparticles with average size of 7 nm. The XRD patterns revealed diffraction peaks at [Formula: see text] and 92.37∘ that was indexed to (1 1 0), (1 1 0), (1 0 0), (1 0 0) and (1 0 0) planes of face-centered cubic (fcc) crystalline structure respectively. The synthesized nanoparticles possess good antioxidant activity with IC50 of [Formula: see text] and [Formula: see text][Formula: see text][Formula: see text]g/ml for DPPH and ABTS, respectively, and inhibit the growth of Staphylococcus faecalis and Bacillus cereus with MIC of 25 and 15[Formula: see text][Formula: see text]g/ml respectively. AS-AgNPs also revealed higher cytotoxic efficacy against MDA-MB-231 breast cancer cells with IC50 of [Formula: see text][Formula: see text][Formula: see text]g/ml. AS-AgNPs showed acceptable size and shape of nanoparticles and could therefore be a potential source of antimicrobial and anticancer agents. It can be concluded that the synthesized AS-AgNPs is a good source of anticancer agent with broad spectrum of antibiotic activity.

APA, Harvard, Vancouver, ISO, and other styles

5

Bondon, Nicolas, Denis Durand, Kamel Hadj-Kaddour, Lamiaa M. A. Ali, Rabah Boukherroub, Nadir Bettache, Magali Gary-Bobo, et al. "Photosensitivity of Different Nanodiamond–PMO Nanoparticles in Two-Photon-Excited Photodynamic Therapy." Life 12, no. 12 (December 7, 2022): 2044. http://dx.doi.org/10.3390/life12122044.

Full text

Abstract:

Background: In addition to their great optical properties, nanodiamonds (NDs) have recently proved useful for two-photon-excited photodynamic therapy (TPE-PDT) applications. Indeed, they are able to produce reactive oxygen species (ROS) directly upon two-photon excitation but not with one-photon excitation; Methods: Fluorescent NDs (FNDs) with a 100 nm diameter and detonation NDs (DNDs) of 30 nm were compared. In order to use the gems for cancer-cell theranostics, they were encapsulated in a bis(triethoxysilyl)ethylene-based (ENE) periodic mesoporous organosilica (PMO) shell, and the surface of the formed nanoparticles (NPs) was modified by the direct grafting of polyethylene glycol (PEG) and amino groups using PEG-hexyltriethoxysilane and aminoundecyltriethoxysilane during the sol–gel process. The NPs’ phototoxicity and interaction with MDA-MB-231 breast cancer cells were evaluated afterwards; Results: Transmission electronic microscopy images showed the formation of core–shell NPs. Infrared spectra and zeta-potential measurements confirmed the grafting of PEG and NH2 groups. The encapsulation of the NDs allowed for the imaging of cancer cells with NDs and for the performance of TPE-PDT of MDA-MB-231 cancer cells with significant mortality. Conclusions: Multifunctional ND@PMO core–shell nanosystems were successfully prepared. The NPs demonstrated high biocompatibility and TPE-PDT efficiency in vitro in the cancer cell model. Such systems hold good potential for two-photon-excited PDT applications.

APA, Harvard, Vancouver, ISO, and other styles

6

Karakatsanis, A., K. Daskalakis, P. Stålberg, H. Olofsson, Y. Andersson, S. Eriksson, L. Bergkvist, and F. Wärnberg. "Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer." British Journal of Surgery 104, no. 12 (September 6, 2017): 1675–85. http://dx.doi.org/10.1002/bjs.10606.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kutwin, Marta, Ewa Sawosz, Sławomir Jaworski, Mateusz Wierzbicki, Barbara Strojny, Marta Grodzik, Malwina Ewa Sosnowska, Maciej Trzaskowski, and André Chwalibog. "Nanocomplexes of Graphene Oxide and Platinum Nanoparticles against Colorectal Cancer Colo205, HT-29, HTC-116, SW480, Liver Cancer HepG2, Human Breast Cancer MCF-7, and Adenocarcinoma LNCaP and Human Cervical Hela B Cell Lines." Materials 12, no. 6 (March 19, 2019): 909. http://dx.doi.org/10.3390/ma12060909.

Full text

Abstract:

Inefficient drug administration into cancer cells is related to the chemoresistance of cancer cells caused by genetic mutations including genes involved in drug transport, enzyme metabolism, and/or DNA damage repair. The objective of the present study was to evaluate the properties of platinum (NP-Pt), graphene oxide (GO), and the nanocomplex of GO functionalized with platinum nanoparticles (GO-NP-Pt) against several genetically, phenotypically, and metabolically different cancer cell lines: Colo205, HT-29, HTC-116, SW480, HepG2, MCF-7, LNCaP, and Hela B. The anticancer effects toward the cancer cell lines were evaluated by 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxyanilide salt (XTT) and bromodeoxyuridine (BrdU) assays and measurements of cell apoptosis and morphology deformations. The NP-Pt and GO could effectively be introduced to cancer cells, but more effective delivery was observed after GO-NP-Pt treatment. The delivery of the GO-NP-Pt nanocomplex significantly decreased the viability of Colo 205 and HepG2 cells, but did not increase the cytotoxicity of other investigated cancer cells. The nanocomplex GO-NP-Pt also significantly increased the apoptosis of Colo 205 and HepG2 cancer cells. The obtained results suggest that the nanocomplex GO-NP-Pt is a remarkable nanostructure that can improve the delivery of Pt nanoparticles into cancer cells and has potential anticancer applications.

APA, Harvard, Vancouver, ISO, and other styles

8

Riley, Rachel, Rachel O’Sullivan, Andrea Potocny, Joel Rosenthal, and Emily Day. "Evaluating Nanoshells and a Potent Biladiene Photosensitizer for Dual Photothermal and Photodynamic Therapy of Triple Negative Breast Cancer Cells." Nanomaterials 8, no. 9 (August 25, 2018): 658. http://dx.doi.org/10.3390/nano8090658.

Full text

Abstract:

Light-activated therapies are ideal for treating cancer because they are non-invasive and highly specific to the area of light application. Photothermal therapy (PTT) and photodynamic therapy (PDT) are two types of light-activated therapies that show great promise for treating solid tumors. In PTT, nanoparticles embedded within tumors emit heat in response to laser light that induces cancer cell death. In PDT, photosensitizers introduced to the diseased tissue transfer the absorbed light energy to nearby ground state molecular oxygen to produce singlet oxygen, which is a potent reactive oxygen species (ROS) that is toxic to cancer cells. Although PTT and PDT have been extensively evaluated as independent therapeutic strategies, they each face limitations that hinder their overall success. To overcome these limitations, we evaluated a dual PTT/PDT strategy for treatment of triple negative breast cancer (TNBC) cells mediated by a powerful combination of silica core/gold shell nanoshells (NSs) and palladium 10,10-dimethyl-5,15-bis(pentafluorophenyl)biladiene-based (Pd[DMBil1]-PEG750) photosensitizers (PSs), which enable PTT and PDT, respectively. We found that dual therapy works synergistically to induce more cell death than either therapy alone. Further, we determined that low doses of light can be applied in this approach to primarily induce apoptotic cell death, which is vastly preferred over necrotic cell death. Together, our results show that dual PTT/PDT using silica core/gold shell NSs and Pd[DMBil1]-PEG750 PSs is a comprehensive therapeutic strategy to non-invasively induce apoptotic cancer cell death.

APA, Harvard, Vancouver, ISO, and other styles

9

Chiu, Hock Ing, Che Nurul Azieyan Che Mood, Nur Nadhirah Mohamad Zain, Muggundha Raoov Ramachandran, Noorfatimah Yahaya, Nik Nur Syazni Nik Mohamed Kamal, Wai Hau Tung, Yoke Keong Yong, Chee Keong Lee, and Vuanghao Lim. "Biogenic Silver Nanoparticles of Clinacanthus nutans as Antioxidant with Antimicrobial and Cytotoxic Effects." Bioinorganic Chemistry and Applications 2021 (May 13, 2021): 1–11. http://dx.doi.org/10.1155/2021/9920890.

Full text

Abstract:

Silver nanoparticles (AgNPs) previously synthesised using leaf (AgNP-L) and stem (AgNP-S) extracts of Clinacanthus nutans (C. nutans) were tested to evaluate antimicrobial, antioxidant, and cytotoxicity activities. The AgNPs showed good inhibition against bacteria, but not fungi. The inhibition results showed the highest activity against Staphylococcus aureus (S. aureus) with 11.35 mm (AgNP-L) and 11.52 mm (AgNP-S), while the lowest inhibition was against Escherichia coli (E. coli) with 9.22 mm (AgNP-L) and 9.25 mm (AgNP-S) in the disc diffusion method. The same trend of results was noted in the well diffusion method. The IC50 of AgNP-L and AgNP-S in 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) assays was 417.05 μg/mL and 434.60 μg/mL, as well as 304.31 μg/mL and 326.83 μg/mL, respectively. Ferric reducing power (FRAP) assay showed that AgNP-L [872.389 μmol/L Fe(II)] and AgNP-S [612.770 μmol/L Fe(II)] exhibited significantly ( p < 0.05) greater antioxidant activities than leaf extract (CNL) [152.260 μmol/L Fe(II)] and stem extract (CNS) [110.445 μmol/L Fe(II)] of C. nutans. The AgNPs were also proven to possess cytotoxic effects on the breast (MCF-7), cervical (HeLa), and colon (HT-29) cancer cells in a dose-dependent manner. AgNP-S and AgNP-L showed significantly ( p < 0.05) higher cytotoxicity against MCF-7 (117.43 μg/mL) and HT-29 (78.47 μg/mL), respectively. In conclusion, the biosynthesised AgNPs from aqueous extract leaves and stem of C. nutans have demonstrated promising potential towards antioxidant, antimicrobial, and cytotoxicity activities.

APA, Harvard, Vancouver, ISO, and other styles

10

Koppiker, Chaitanyanand B., Santosh Dixit, Aijaz Ul Noor, Laleh Busheri, Gail Lebovic, Gautam Sharan, Upendra Dhar, and Smeeta Nare. "Breast Oncoplasty Surgery in Low- and Middle-Income Countries: Lessons From India." Journal of Global Oncology 4, Supplement 3 (October 2018): 22s. http://dx.doi.org/10.1200/jgo.18.10250.

Full text

Abstract:

Purpose Breast cancer is the most common cancer in India, affecting all socio-economic strata. Despite its growing global acceptance, Breast Oncoplasty Surgery (BOS) remains nascent in India, necessitating local context-specific innovative delivery models for clinicians and the general public. Here, we present experiences from Orchids Breast Health Clinic (OBHC; Pune, India) with the implementation of BOS clinical services, training, and research and community outreach. Methods OBHC, a dedicated breast unit, has established the first dedicated BOS clinic in India, conducted hands-on training workshops for trainee surgeons, developed an MCh degree program in breast oncoplasty with the University of East Anglia (Norwich, United Kingdom), undertaken BOS research in Indian patients, and created outreach programs to popularize BOS. Results A cost-effective one surgeon–dual role concept wherein the same surgeon performs onco- and plastic surgery and one-stage implant-based breast reconstruction has been adopted. Since 2013, BOS cases included BCS (n = 440), breast reconstruction (n = 210), and therapeutic mammoplasty (n = 135). The unavailability of acellular dermal matrices has prompted the innovation of a surgical technique, termed Advanced Autologous Dermal Sling, which uses vascularized local tissue as implant cover. Significant improvement in postsurgery outcomes and protection against radiation complications has been observed. BOS hospitalization costs have been reduced by 50% thereby, which has led to high rates of acceptance (80%) of BOS in patients at OBHC. Young breast surgeons from across India and South Asian Association for Regional Cooperation countries have enrolled in the MCh degree program, which involves an embedded curriculum with online didactic modules and hands-on training workshops in Pune, India. Longitudinal follow-up after 1, 3, and 5 years postsurgery in the study cohorts is undertaken for post-BOS outcomes using clinical assessment (Bakers scale) and patient-reported outcomes measures (BREAST-Q questionnaire). Multiple research projects are undergoing peer-review before publication. To increase awareness of BOS among Indian women, community awareness campaigns with the theme of Losing Is Not an Option are underway via public talks, symposia, marathon, and op-eds in electronic and print media. Conclusion The OBHC model of Affordable Excellence in BOS, developed in the Indian context, can be extrapolated to benefit patients with breast cancer from other low- and middle-income countries. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc . No COIs from the authors.

APA, Harvard, Vancouver, ISO, and other styles

11

Lu, Zheng-Rong, and William P. Schiemann. "ECO/siRNA nanoparticles and breast cancer metastasis." Oncoscience 2, no. 10 (August 20, 2015): 823–24. http://dx.doi.org/10.18632/oncoscience.200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Ganesan, Kumar, Yan Wang, Fei Gao, Qingqing Liu, Chen Zhang, Peng Li, Jinming Zhang, and Jianping Chen. "Targeting Engineered Nanoparticles for Breast Cancer Therapy." Pharmaceutics 13, no. 11 (November 1, 2021): 1829. http://dx.doi.org/10.3390/pharmaceutics13111829.

Full text

Abstract:

Breast cancer (BC) is the second most common cancer in women globally after lung cancer. Presently, the most important approach for BC treatment consists of surgery, followed by radiotherapy and chemotherapy. The latter therapeutic methods are often unsuccessful in the treatment of BC because of their various side effects and the damage incurred to healthy tissues and organs. Currently, numerous nanoparticles (NPs) have been identified and synthesized to selectively target BC cells without causing any impairments to the adjacent normal tissues or organs. Based on an exploratory study, this comprehensive review aims to provide information on engineered NPs and their payloads as promising tools in the treatment of BC. Therapeutic drugs or natural bioactive compounds generally incorporate engineered NPs of ideal sizes and shapes to enhance their solubility, circulatory half-life, and biodistribution, while reducing their side effects and immunogenicity. Furthermore, ligands such as peptides, antibodies, and nucleic acids on the surface of NPs precisely target BC cells. Studies on the synthesis of engineered NPs and their impact on BC were obtained from PubMed, Science Direct, and Google Scholar. This review provides insights on the importance of engineered NPs and their methodology for validation as a next-generation platform with preventive and therapeutic effects against BC.

APA, Harvard, Vancouver, ISO, and other styles

13

Shakil, Md Salman, Md Ashraful Hasan, and Satya Ranjan Sarker. "Iron Oxide Nanoparticles for Breast Cancer Theranostics." Current Drug Metabolism 20, no. 6 (July 17, 2019): 446–56. http://dx.doi.org/10.2174/1389200220666181122105043.

Full text

Abstract:

Background: Breast cancer is the second leading cause of death in women worldwide. The extremely fast rate of metastasis and ability to develop resistance mechanism to all the conventional drugs make them very difficult to treat which are the causes of high morbidity and mortality of breast cancer patients. Scientists throughout the world have been focusing on the early detection of breast tumor so that treatment can be started at the very early stage. Moreover, conventional treatment processes such as chemotherapy, radiotherapy, and local surgery suffer from various limitations including toxicity, genetic mutation of normal cells, and spreading of cancer cells to healthy tissues. Therefore, new treatment regimens with minimum toxicity to normal cells need to be urgently developed. Methods: Iron oxide nanoparticles have been widely used for targeting hyperthermia and imaging of breast cancer cells. They can be conjugated with drugs, proteins, enzymes, antibodies or nucleotides to deliver them to target organs, tissues or tumors using external magnetic field. Results: Iron oxide nanoparticles have been successfully used as theranostic agents for breast cancer both in vitro and in vivo. Furthermore, their functionalization with drugs or functional biomolecules enhance their drug delivery efficiency and reduces the systemic toxicity of drugs. Conclusion: This review mainly focuses on the versatile applications of superparamagnetic iron oxide nanoparticles on the diagnosis, treatment, and detecting progress of breast cancer treatment. Their wide application is because of their excellent superparamagnetic, biocompatible and biodegradable properties.

APA, Harvard, Vancouver, ISO, and other styles

14

Herrera Estrada, Lina, Trudy J. Padmore, and Julie A. Champion. "Bacterial Effector Nanoparticles as Breast Cancer Therapeutics." Molecular Pharmaceutics 13, no. 3 (January 22, 2016): 710–19. http://dx.doi.org/10.1021/acs.molpharmaceut.5b00377.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Jiang, Yanyan, Nan Lin, Sheng Huang, Chongping Lin, Na Jin, Zaizhong Zhang, Jun Ke, Yinghao Yu, Jianping Zhu, and Yu Wang. "Tracking Nonpalpable Breast Cancer for Breast-conserving Surgery With Carbon Nanoparticles." Medicine 94, no. 10 (March 2015): e605. http://dx.doi.org/10.1097/md.0000000000000605.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Alqaraghuli, Hasanain Gomhor J., Soheila Kashanian, and Ronak Rafipour. "A Review on Targeting Nanoparticles for Breast Cancer." Current Pharmaceutical Biotechnology 20, no. 13 (October 28, 2019): 1087–107. http://dx.doi.org/10.2174/1389201020666190731130001.

Full text

Abstract:

Chemotherapeutic agents have been used extensively in breast cancer remedy. However, most anticancer drugs cannot differentiate between cancer cells and normal cells, leading to toxic side effects. Also, the resulted drug resistance during chemotherapy reduces treatment efficacy. The development of targeted drug delivery offers great promise in breast cancer treatment both in clinical applications and in pharmaceutical research. Conjugation of nanocarriers with targeting ligands is an effective therapeutic strategy to treat cancer diseases. In this review, we focus on active targeting methods for breast cancer cells through the use of chemical ligands such as antibodies, peptides, aptamers, vitamins, hormones, and carbohydrates. Also, this review covers all information related to these targeting ligands, such as their subtypes, advantages, disadvantages, chemical modification methods with nanoparticles and recent published studies (from 2015 to present). We have discussed 28 different targeting methods utilized for targeted drug delivery to breast cancer cells with different nanocarriers delivering anticancer drugs to the tumors. These different targeting methods give researchers in the field of drug delivery all the information and techniques they need to develop modern drug delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

17

Marshall, Suphalak Khamruang, Pavimol Angsantikul, Zhiqing Pang, Norased Nasongkla, Rusnah Syahila Duali Hussen, and Soracha D. Thamphiwatana. "Biomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment." Molecules 27, no. 19 (October 1, 2022): 6473. http://dx.doi.org/10.3390/molecules27196473.

Full text

Abstract:

The development of biomimetic drug delivery systems for biomedical applications has attracted significant research attention. As the use of cell membrane as a surface coating has shown to be a promising platform for several disease treatments. Cell-membrane-coated nanoparticles exhibit enhanced immunocompatibility and prolonged circulation time. Herein, human red blood cell (RBC) membrane-cloaked nanoparticles with enhanced targeting functionality were designed as a targeted nanotheranostic against cancer. Naturally, derived human RBC membrane modified with targeting ligands coated onto polymeric nanoparticle cores containing both chemotherapy and imaging agent. Using epithelial cell adhesion molecule (EpCAM)-positive MCF-7 breast cancer cells as a disease model, the nature-inspired targeted theranostic human red blood cell membrane-coated polymeric nanoparticles (TT-RBC-NPs) platform was capable of not only specifically binding to targeted cancer cells, effectively delivering doxorubicin (DOX), but also visualizing the targeted cancer cells. The TT-RBC-NPs achieved an extended-release profile, with the majority of the drug release occurring within 5 days. The TT-RBC-NPs enabled enhanced cytotoxic efficacy against EpCAM positive MCF-7 breast cancer over the non-targeted NPs. Additionally, fluorescence images of the targeted cancer cells incubated with the TT-RBC-NPs visually indicated the increased cellular uptake of TT-RBC-NPs inside the breast cancer cells. Taken together, this TT-RBC-NP platform sets the foundation for the next-generation stealth theranostic platforms for systemic cargo delivery for treatment and diagnostic of cancer.

APA, Harvard, Vancouver, ISO, and other styles

18

Hosseinkazemi, Hessam, Saeed Samani, Andrew O’Neill, Mahdieh Soezi, Mohsen Moghoofei, Mohammad H. Azhdari, Farzaneh Aavani, Abolfazl Nazbar, Saeed Heidari Keshel, and Mohammad Doroudian. "Applications of Iron Oxide Nanoparticles against Breast Cancer." Journal of Nanomaterials 2022 (May 12, 2022): 1–12. http://dx.doi.org/10.1155/2022/6493458.

Full text

Abstract:

Breast cancer is the most common cancer diagnosed in women, with an estimated 12% of women in the United States affected during their lifetime. Researchers have demonstrated that early detection, diagnosis, and treatment are pivotal to increasing survival. The advent of nanotechnology has yielded several novel advances and available modern methods within the clinic to detect and treat breast cancer. Inorganic nanoparticles are broadly utilized for cancer diagnosis and therapeutic purposes. Interestingly, these nanoparticles can also be attached to tumor-specific ligands and used to deliver chemotherapeutic or hormonal agents with high levels of tumor selectivity. Iron oxide nanoparticles are one of the most commonly used nanomaterials, which have attracted much attention to detect and treat breast cancers, owing to their superparamagnetic characteristics. Computerized tomography and magnetic resonance imaging (MRI) utilizing iron-based magnetic nanoparticles are promising approaches for the radiological detection of breast cancer. Here, we discuss the roles and recent applications of iron oxide nanoparticles in diagnosing and treating breast cancer.

APA, Harvard, Vancouver, ISO, and other styles

19

Yezhelyev, Maksym, Rami Yacoub, and Ruth O’Regan. "Inorganic nanoparticles for predictive oncology of breast cancer." Nanomedicine 4, no. 1 (January 2009): 83–103. http://dx.doi.org/10.2217/17435889.4.1.83.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Ashiq, Muhammad Gul Bahar. "Laser-irradiated gold nanoparticles for breast cancer therapy." Modern Physics Letters B 33, no. 19 (July 8, 2019): 1950217. http://dx.doi.org/10.1142/s0217984919502178.

Full text

Abstract:

Current study involves laser-induced gold nanoparticles (GNPs) for breast cancer therapy. GNPs as a therapeutic agent using nanophotolysis approach are discussed. Coulomb explosion of GNPs is studied numerically using MATLAB. Our findings show that [Formula: see text] ions are generated for short pulse laser interaction of 8 ns and laser irradiation of 2 J/cm2 penetrates in the tumor depth of 3.30 cm. Cluster size of 98 nm produced [Formula: see text] nanobullets that target the breast tumor. Short pulse laser of 2.27 ns generates maximum shock front velocity of [Formula: see text] cm/s. Shock front of 20–146 [Formula: see text]m is produced for effectively damaging the breast cancer tissues. A total of 825 cells are damaged by [Formula: see text] ions. Current results are matched with the literature and are in good correlation. Hence, we conclude that laser-irradiated GNPs using nanophotolysis approach are useful for targeted therapy of breast tumor.

APA, Harvard, Vancouver, ISO, and other styles

21

Goldman, Evgeniya, Assaf Zinger, Dana da Silva, Zvi Yaari, Ashima Kajal, Dikla Vardi-Oknin, Mor Goldfeder, et al. "Nanoparticles target early-stage breast cancer metastasisin vivo." Nanotechnology 28, no. 43 (October 2, 2017): 43LT01. http://dx.doi.org/10.1088/1361-6528/aa8a3d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Liu, Siyan, Jing Li, Lin Gu, Kunzhe Wu, and Hua Xing. "Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer." International Journal of Nanomedicine Volume 17 (November 2022): 5209–27. http://dx.doi.org/10.2147/ijn.s388075.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Wang, Yanjie, Maurice Pasternak, Krishnan Sathiyamoorthy, and Michael C. Kolios. "Anti-HER2 PLGA-PEG polymer nanoparticle containing gold nanorods and paclitaxel for laser-activated breast cancer detection and therapy." Biomedical Optics Express 12, no. 4 (March 18, 2021): 2171. http://dx.doi.org/10.1364/boe.419252.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Sharma, Arun, Nitin Jain, and Rashmi Sareen. "Nanocarriers for Diagnosis and Targeting of Breast Cancer." BioMed Research International 2013 (2013): 1–10. http://dx.doi.org/10.1155/2013/960821.

Full text

Abstract:

Breast cancer nanotherapeutics is consistently progressing and being used to remove the various limitations of conventional method available for the diagnosis and treatment of breast cancer. Nanoparticles provide an interdisciplinary area for research in imaging, diagnosis, and targeting of breast cancer. With advanced physicochemical properties and better bioavailability, they show prolonged blood circulation with efficient tumor targeting. Passive targeting mechanisms by using leaky vasculature, tumor microenvironment, or direct local application and active targeting approaches using receptor antibody, amplification in the ability of nanoparticles to target specific tumor can be achieved. Nanoparticles are able to reduce cytotoxic effect of the active anticancer drugs by increasing cancer cell targeting in comparison to conventional formulations. Various nanoparticles-based formulations are in the preclinical and clinical stages of development; among them, polymeric drug micelles, liposomes, dendrimer, carbon nanotubes, and nanorods are the most common. In this review, we have discussed the role of nanoparticles with respect to oncology, by particularly focusing on the breast cancer and various nanodelivery systems used for targeting action.

APA, Harvard, Vancouver, ISO, and other styles

25

ASHIQ, M. G. B., NOORDDIN IBRAHIM, M. SHAHID, B. A. TAHIR, and M. A. SAEED. "NOVEL NANOPHOTOLYSIS TECHNIQUE FOR BREAST CANCER THERAPY." Modern Physics Letters B 26, no. 23 (August 13, 2012): 1250147. http://dx.doi.org/10.1142/s0217984912501473.

Full text

Abstract:

The aim of this study is to investigate the effects of gold nanoparticles on breast cancer tumor. A theoretical approach has been adopted to probe the nanophotolysis technique using short pulse laser. The influences of various parameters including number of ions, shock front, energy distribution function, laser fluence are discussed in detail. Computational results suggest that spherical gold nanoparticles provides a promising platform for selective killing of abnormal cells in breast cancer tumor.

APA, Harvard, Vancouver, ISO, and other styles

26

Bao, Youmei, Shenqi Zhang, Zeming Chen, Ann T. Chen, Junning Ma, Gang Deng, Weiguo Xu, et al. "Synergistic Chemotherapy for Breast Cancer and Breast Cancer Brain Metastases via Paclitaxel-Loaded Oleanolic Acid Nanoparticles." Molecular Pharmaceutics 17, no. 4 (March 9, 2020): 1343–51. http://dx.doi.org/10.1021/acs.molpharmaceut.0c00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Khathuriya, Rajesh, Shailesh Sharma, Upendra K. Jain, and Jitender Madan. "Formulation and Evaluation of Lycopene Nanoparticles for Breast Cancer." International Journal of Drug Delivery Technology 10, no. 02 (June 25, 2020): 292–94. http://dx.doi.org/10.25258/ijddt.10.2.17.

Full text

Abstract:

Aim: Lycopene is owned to carotenoids that manifest better pharmacological possessions such as antioxidant, anti-inflammatory, and anticancer. As an outcome of very little water solubility, it has a restricted systemic absorption after oral route. Methods: Lycopene-loaded sentinel lymph nodes (SLNs) by hot homogenization method, using some alteration were formulated. The size of nanoparticles (NPs) was characterized using scanning electron microscope (SEM). Also, encapsulation efficiency, drug loading (DL), and drug release were calculated. Results: SEM revealed spherical SLNs. High EE and DL were procured. Conclusion: We formulated a stable lycopene-SLNs with better physicochemical properties.

APA, Harvard, Vancouver, ISO, and other styles

28

Johnson, Laura, Geoff Charles-Edwards, and Michael Douek. "Nanoparticles in Sentinel Lymph Node Assessment in Breast Cancer." Cancers 2, no. 4 (November 17, 2010): 1884–94. http://dx.doi.org/10.3390/cancers2041884.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Prados, Jose, Consolacion Melguizo, Raul Ortiz, Celia Velez, Pablo J. Alvarez, Jose L. Arias, Maria A. Ruiz, Visitacion Gallardo, and Antonia Aranega. "Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy." Anti-Cancer Agents in Medicinal Chemistry 12, no. 9 (October 1, 2012): 1058–70. http://dx.doi.org/10.2174/187152012803529646.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Sun, Bing Feng, and Si Shen Feng. "Trastuzumab Decorated Nanoparticles for Targeted Chemotherapy of Breast Cancer." Advances in Science and Technology 57 (September 2008): 160–65. http://dx.doi.org/10.4028/www.scientific.net/ast.57.160.

Full text

Abstract:

Nanoparticles (NPs) of biodegradable polymers as a drug delivery system formulate drug devoid of harmful adjuvant, realize controlled drug release and achieve better therapeutic efficacy than pristine agent. However, the low selectivity of NPs towards cancer cells hinders the advantages of NP formulation for efficient chemotherapy. The novel system of paclitaxel-loaded, trastuzumab-decorated poly(D,L-lactide-co-glycolide)/montmorillonite(PLGA/MMT) NPs for targeted drug delivery was developed. Paclitaxel was used as a prototype drug with excellent therapeutic effects against a wide spectrum of cancers. Trastuzumab is a humanized monoclonal antibody directed against the human epidermal growth factor receptor-2(HER2), which overexpresses in 25-30% breast cancers. Moreover, synergistic effects have been found in combination of trastuzumab with paclitaxel. As a potent detoxifier, the medical clay MMT can adsorb toxins and reduce side effects. The drug delivery system represents a new concept in developing drug delivery systems and can achieve functions such as to formulate anticancer drugs with no harmful adjuvant; to reduce side effects caused by formulated drugs; to have synergistic therapeutic effects; and to achieve targeted chemotherapy for HER2-positive breast cancer

APA, Harvard, Vancouver, ISO, and other styles

31

Shahgolzari, Mehdi, Hassan Dianat-Moghadam, Afagh Yavari, Steven N. Fiering, and Kathleen Hefferon. "Multifunctional Plant Virus Nanoparticles for Targeting Breast Cancer Tumors." Vaccines 10, no. 9 (August 30, 2022): 1431. http://dx.doi.org/10.3390/vaccines10091431.

Full text

Abstract:

Breast cancer treatment using plant-virus-based nanoparticles (PVNPs) has achieved considerable success in preclinical studies. PVNP-based breast cancer therapies include non-targeted and targeted nanoplatforms for delivery of anticancer therapeutic chemo and immune agents and cancer vaccines for activation of local and systemic antitumor immunity. Interestingly, PVNP platforms combined with other tumor immunotherapeutic options and other modalities of oncotherapy can improve tumor efficacy treatment. These applications can be achieved by encapsulation of a wide range of active ingredients and conjugating ligands for targeting immune and tumor cells. This review presents the current breast cancer treatments based on PVNP platforms.

APA, Harvard, Vancouver, ISO, and other styles

32

Marrache, Sean, Joshua H. Choi, Smanla Tundup, Dhillon Zaver, Donald A. Harn, and Shanta Dhar. "Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer." Integrative Biology 5, no. 1 (July 26, 2012): 215–23. http://dx.doi.org/10.1039/c2ib20125a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Kim, Sun-Jung, Pan Kee Bae, and Bong Hyun Chung. "Self-assembled levan nanoparticles for targeted breast cancer imaging." Chemical Communications 51, no. 1 (2015): 107–10. http://dx.doi.org/10.1039/c4cc07679f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Li, Jinmao, Xiaojun Yang, Ping Yang, and Fangning Gao. "Hyaluronic acid–conjugated silica nanoparticles for breast cancer therapy." Inorganic and Nano-Metal Chemistry 47, no. 5 (August 19, 2016): 777–82. http://dx.doi.org/10.1080/15533174.2016.1218509.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Mu, Qingxin, Hui Wang, and Miqin Zhang. "Nanoparticles for imaging and treatment of metastatic breast cancer." Expert Opinion on Drug Delivery 14, no. 1 (July 19, 2016): 123–36. http://dx.doi.org/10.1080/17425247.2016.1208650.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Núñez, Cristina, Sergio Vázquez Estévez, and María del Pilar Chantada. "Inorganic nanoparticles in diagnosis and treatment of breast cancer." JBIC Journal of Biological Inorganic Chemistry 23, no. 3 (February 16, 2018): 331–45. http://dx.doi.org/10.1007/s00775-018-1542-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Aznar, María Ángela, Beatriz Lasa-Saracíbar, Ander Estella-Hermoso de Mendoza, and María José Blanco-Prieto. "Efficacy of edelfosine lipid nanoparticles in breast cancer cells." International Journal of Pharmaceutics 454, no. 2 (October 2013): 720–26. http://dx.doi.org/10.1016/j.ijpharm.2013.04.068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Blanco, Elvin, Takafumi Sangai, Angela Hsiao, Silvia Ferrati, Litao Bai, Xuewu Liu, Funda Meric-Bernstam, and Mauro Ferrari. "Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment." Cancer Letters 334, no. 2 (July 2013): 245–52. http://dx.doi.org/10.1016/j.canlet.2012.07.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Dongsar, Tenzin Tsering, Tenzin Sonam Dongsar, Mohammed A. S. Abourehab, Neelima Gupta, and Prashant Kesharwani. "Emerging application of magnetic nanoparticles for breast cancer therapy." European Polymer Journal 187 (April 2023): 111898. http://dx.doi.org/10.1016/j.eurpolymj.2023.111898.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Yıldırım, Metin, Ömür Acet, Derya Yetkin, Burcu Önal Acet, Veyis Karakoc, and Mehmet Odabası. "Anti-cancer activity of naringenin loaded smart polymeric nanoparticles in breast cancer." Journal of Drug Delivery Science and Technology 74 (August 2022): 103552. http://dx.doi.org/10.1016/j.jddst.2022.103552.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Fisher, M., F. McRae, M. Pitcher, I. Hornung, and J. Spence. "Bridge of Support: A Collaborative Approach to a Peer Support Program." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 169s. http://dx.doi.org/10.1200/jgo.18.74600.

Full text

Abstract:

Background and context: The Bridge of Support Program (BOS) is adapting a successful community based model of peer support to an acute setting, at the Sunshine Hospital Breast Clinic, to meet the cultural and socioeconomic diverse needs of women with breast cancer. This two year project was funded by LUCRF Community Partnership Trust. Aim: To improve the experience of women undergoing treatment of breast cancer at Western Health. To improve access to psych-social, emotional and practical support for women by extending the reach of CounterPart- a state-wide service of women´s Health Victoria, funded by the Victorian Department of Health and Human Services to provide peer support and information to people affected by breast or a gynecologic cancer. Program/Policy process: Peer support volunteers actively guided women to current and credible evidence-based information, support decision making and provide emotional support. Peer support volunteers are rostered once a week at Sunshine Hospital to coincide with breast clinic and include access to the day oncology unit and radiotherapy center. Detailed contact information is recorded and women receive follow-up contact (with consent) from the peer support volunteers at the CounterPart Resource Centre in Melbourne. A CounterPart staff member oversees the project and provides direct support and supervision to the volunteers on site at the hospital. Women can self refer. Outcomes: Between February and December 2016 the BOS program had 159 separate contacts with patients and their families. 82 contacts were with men and women who were new to CounterPart and 77 were follow-up contacts. 90 individuals treated for breast cancer at Western Health accessed the program, which represent 53% of the women seen by the breast service. 48% of the contacts were follow-up contacts with the CounterPart volunteers indicating that once engaged with the service many men and women continue to make contact. 38% of contacts were with women diagnosed with metastatic disease, a group who often have higher levels of unmet or more complex needs. 49% were born in a nonmain English speaking country (compared with the overall state of Victoria average of 19.6%) thus reflecting an accessible service to the non-English speaking community. What was learned: At a time when peer support is being increasingly recognized as a key part of effective supportive care in cancer services, the BOS program offers a model of integrated peer support that is respected, reliable, well supported and safe within the acute setting. This acute-community sector partnership demonstrates how the medical and social models of health care can work together to provide a connected and quality service for men and women diagnosed with breast cancer. An active research approach is enabling the project to be responsive to issues and challenges as they arise including the ongoing recruitment of women as volunteers from the local community to work within the acute setting.

APA, Harvard, Vancouver, ISO, and other styles

42

Thagele, Rajkumari, Archana Bagre, and Mohan Lal Kori. "Chitosan anchored nanoparticles for breast cancer: preparation and evaluation: part-I." Journal of Drug Delivery and Therapeutics 9, no. 1 (January 15, 2019): 1–5. http://dx.doi.org/10.22270/jddt.v9i1.2151.

Full text

Abstract:

The objective of present research work was to develop methotrexate loaded chitosan anchored shell nanoparticles for drug delivery in breast cancer. Chitosan nanoparticles (CS-NPs) were synthesized by ionic gelation of chitosan using sodium tripolyphosphate (STPP). The optimized nanoparticles were characterized for particle size and polydispersity index (PDI) revealed particle size were found to be between 57.08 nm to169.5 nm and PDI 0.252 to 0.639 respectively. The results signpost that stirring speed during ionic gelation reaction was also decisive parameters for the size of the nanoparticles obtained. Further characterization involved to show polymer-drug interaction was FTIR and DSC. This paper grants a revision of the physical factors elaborate in attaining nanoparticles in order to regulate the particle size of polymeric nanoparticles made from chitosan, without any surplus chemical treatment. Keywords: Breast cancer, Nanoparticles, Chitosan, Methotrexate

APA, Harvard, Vancouver, ISO, and other styles

43

Shen, Ye, Lianming Zhou, Meiyu Xu, Zhanhai Tan, Kai Yao, and Guanghui Zhu. "Killing Action of Cuprous Oxide Nanoparticles on Breast Cancer Cells." Nanoscience and Nanotechnology Letters 12, no. 10 (October 1, 2020): 1233–38. http://dx.doi.org/10.1166/nnl.2020.3223.

Full text

Abstract:

Breast cancer (BC), a common malignancy, is intractable at present. Cuprous oxide nanoparticles (Conps) are new nanoparticles crucial in inhibiting tumor progression according to early studies, but their role in BC remains unclear. Field emission-scanning electron microscopy (FESEM) and field emission–transmission electron microscopy (FETEM) were used for the morphological observation of Conps, and energy-dispersive X-ray spectroscopy was used for their elemental composition analysis. Multipoint nitrogen adsorption was used to determine the Brunauer–Emmet–Teller of Conps, and their mean hydrodynamic size and zeta potential in water and intact cell medium were determined by dynamic light scattering (DLS). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, Cell Counting Kit-8, Transwell assay, and flow cytometry were used to determine the effects of Conps on the biological function of BC cells. Western blotting was used to determine the changes in apoptosis-related proteins. Using FESEM and FETEM based on DLS and zeta potential determination, Conps was successfully constructed. Conps significantly lowered the viability of BC cells in a dose-dependent manner, significantly inhibited cell proliferation, invasion, and migration activities, and induced cell apoptosis. Western blotting demonstrated that Conps up-regulated Bax and caspase-3 proteins and down-regulated Bcl-2 protein. The results suggest that Conps can suppress the proliferation, invasion, and migration of BC cells and accelerate their apoptosis. This is a new potential strategy for the clinical treatment of BC.

APA, Harvard, Vancouver, ISO, and other styles

44

Juan, Alberto, Francisco J. Cimas, Iván Bravo, Atanasio Pandiella, Alberto Ocaña, and Carlos Alonso-Moreno. "Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment." International Journal of Molecular Sciences 21, no. 17 (August 21, 2020): 6018. http://dx.doi.org/10.3390/ijms21176018.

Full text

Abstract:

Breast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop novel therapeutics for the treatment of solid tumors. In this regard, targeted therapies can be encapsulated into nanocarriers, and these nanovehicles are guided to the tumors through conjugation with antibodies—the so-called antibody-conjugated nanoparticles (ACNPs). ACNPs can preserve the chemical structure of drugs, deliver them in a controlled manner, and reduce toxicity. As certain breast cancer subtypes and indications have limited therapeutic options, this field provides hope for the future treatment of patients with difficult to treat breast cancers. In this review, we discuss the application of ACNPs for the treatment of this disease. Given the fact that ACNPs have shown clinical activity in this clinical setting, special emphasis on the role of the nanovehicles and their translation to the clinic is placed on the revision.

APA, Harvard, Vancouver, ISO, and other styles

45

Kunde, Shalvi Sinai, and Sarika Wairkar. "Targeted delivery of albumin nanoparticles for breast cancer: A review." Colloids and Surfaces B: Biointerfaces 213 (May 2022): 112422. http://dx.doi.org/10.1016/j.colsurfb.2022.112422.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Singh, Bijay, Sushila Maharjan, Daniel C. Pan, Zongmin Zhao, Yongsheng Gao, Yu Shrike Zhang, and Samir Mitragotri. "Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer." Biomaterials 280 (January 2022): 121302. http://dx.doi.org/10.1016/j.biomaterials.2021.121302.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Sitia, Leopoldo, Marta Sevieri, Lorena Signati, Arianna Bonizzi, Arianna Chesi, Francesco Mainini, Fabio Corsi, and Serena Mazzucchelli. "HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment." Cancers 14, no. 10 (May 13, 2022): 2424. http://dx.doi.org/10.3390/cancers14102424.

Full text

Abstract:

Human epidermal growth factor receptor-2 (HER-2) overexpressing breast cancer is a breast cancer subtype characterized by high aggressiveness, high frequency of brain metastases and poor prognosis. HER-2, a glycoprotein belonging to the ErbB receptor family, is overexpressed on the outer membrane of cancer cells and has been an important therapeutic target for the development of targeted drugs, such as the monoclonal antibodies trastuzumab and pertuzumab. These therapies have been available in clinics for more than twenty years. However, despite the initial enthusiasm, a major issue emerged limiting HER-2 targeted therapy efficacy, i.e., the evolution of drug resistance, which could be tackled by nanotechnology. The aim of this review is to provide a first critical update on the different types of HER-2-targeted nanoparticles that have been proposed in the literature in the last decade for therapeutic purposes. We focus on the different targeting strategies that have been explored, their relative outcomes and current limitations that still need to be improved. Then, we review the nanotools developed as diagnostic kits, focusing on the most recent techniques, which allow accurate quantification of HER-2 levels in tissues, with the aim of promoting more personalized medicinal approaches in patients.

APA, Harvard, Vancouver, ISO, and other styles

48

Iyisan, Banu, Johanna Simon, Yuri Avlasevich, Stanislav Baluschev, Volker Mailaender, and Katharina Landfester. "Antibody-Functionalized Carnauba Wax Nanoparticles to Target Breast Cancer Cells." ACS Applied Bio Materials 5, no. 2 (January 3, 2022): 622–29. http://dx.doi.org/10.1021/acsabm.1c01090.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Hu, Qiong, Zhenzhu Wang, Chong Fan, Qing Wang, Ting Luan, Aiwen Wu, Zhichong Wang, et al. "Biosynthetic Luminescent Ag Nanoparticles in Functionalization for Breast Cancer Therapy." Journal of Biomedical Nanotechnology 18, no. 6 (June 1, 2022): 1553–61. http://dx.doi.org/10.1166/jbn.2022.3361.

Full text

Abstract:

Breast cancer is still the most common malignant tumor in the world despite the research and technique advances. However, how to come true targeted controlled release perplexing the clinicians all the time and rapid development of nanotechnology, as well as emerging microRNA (miRNA), offers an opportunity for diagnosis and treatment of breast cancer. Here, nude mouse model with breast cancer was built and silver nanoparticles (Ag-NPs, ANPs) with near infrared characteristic were biosynthesized. Then, RNA-seq, western blot analysis, and immunofluorescence of the differential expression spectrum of cultured mouse T cells treated by silver nitrate in vitro hinted that biosynthesis of ANPs in cells depended on participation of ferritin and serum albumin (SA). Subsequently, ANPs loaded with miR-200c (miR-200c@ANPs) in vivo and in vitro showed its well property of intelligent controlled release, function of targeted imaging, and potential targeted therapy. The present data indicated that biosynthesized miR-200c@ANPs was equipped with biocompatibility, intelligent controlled release drug, tumor targeting therapy, as well as the visual function. More, this method may be a promising alternative option for diagnosis and treatment of breast cancer.

APA, Harvard, Vancouver, ISO, and other styles

50

Zhang, Yanmin, Shuoxing Jiang, Dongdong Zhang, Xiaoguang Bai, Sidney M. Hecht, and Shengxi Chen. "DNA–affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2." Chemical Communications 53, no. 3 (2017): 573–76. http://dx.doi.org/10.1039/c6cc08495h.

Full text

Abstract:

A DNA tetrahedron–affibody–drug nanoparticle is a highly efficient tool to deliver doxorubicin (DOX) to HER2 overexpressing cancer cells specifically. It represents a highly efficacious agent for selectively inhibiting cancer cells which overexpress HER2 receptor.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!